Tampa, Florida, United States – TheNewswire – June 10, 2025 – CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH) is awaiting information on our grant with Johns Hopkins University for clinical trials with the NIH utilizing our patented technology for a smoking cessation product. Additionally, we are not aware of any delays for this grant with the NIH.

CTT has spoken with the program officer at the NSF in regards to the reviewers comments which were very positive about our patented technology. CTT will make the necessary changes and will add one of its scientists who has won multiple grant awards as the Principal Investigator(PI) for a resubmission . This resubmission will happen on or before July 2, 2025 and CTT will keep shareholders updated on this grant.

 

Additional Corporate Updates for CTT Pharma:

• CTT will file a SBA loan in the next week to raise capital for manufacturing.  

• CTT's CEO is in conversations with several companies for utilizing our technology.   

• Our scientist is in the process of applying for a new grant utilizing an active ingredient not used in previous grants.  

• Our patent office in the process of strengthening our patents in the United States and Europe.  

• The PCAOB audit firm that CTT hired successfully completed an audit for 2024. CTT now has 3 years of PCAOB audits completed.  

• The CEO will be doing a shareholder conference call and will inform investors in the near future. 

• Uplisted to the OTCQB in March 2025. 

CTT Pharma – 813-606-0060